Korro Bio holder plans sale of 5 shares of stock

Rhea-AI Filing Summary

Korro Bio, Inc. (KRRO) is the issuer for a Rule 144 notice filed on behalf of James O. Dolan for a planned sale of 5 shares of common stock, with an aggregate market value of $68.58, when 14,725,646 shares of common stock were outstanding as of September 11, 2026.

Key Figures

Shares to be sold under Rule 144: 5 shares Aggregate market value of shares to be sold: $68.58 Shares outstanding: 14,725,646 shares +5 more

8 metrics

Shares to be sold under Rule 144 5 shares Planned sale of Korro Bio common stock under Rule 144

Aggregate market value of shares to be sold $68.58 Value of 5 shares of Korro Bio common stock covered by the notice

Shares outstanding 14,725,646 shares Korro Bio common stock outstanding as of September 11, 2026

Shares sold June 16, 2026 3,383 shares Sale of Korro Bio common stock on June 16, 2026

Proceeds June 16, 2026 sale $36,638.23 Value of shares sold on June 16, 2026

Shares sold September 8, 2026 7,347 shares Sale of Korro Bio common stock on September 8, 2026

Proceeds September 8, 2026 sale $99,285.52 Value of shares sold on September 8, 2026

Shares sold September 9, 2026 6 shares Sale of Korro Bio common stock on September 9, 2026

Key Terms

Rule 144, Restricted Stock Vesting, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 06/15/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as attorney-in-fact for James O. Dolan."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for KRRO?

It discloses a planned Rule 144 sale of 5 shares of Korro Bio common stock for an aggregate market value of $68.58, when 14,725,646 shares of common stock were outstanding as of September 11, 2026.

Who is the selling security holder in the KRRO Form 144?

The selling security holder is James O. Dolan, for whose account the securities are to be sold. The notice is signed by Emily Navaro as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for James O. Dolan.

How many KRRO shares are covered by this Rule 144 notice?

The notice covers a proposed sale of 5 shares of Korro Bio common stock under Rule 144, with an aggregate market value stated as $68.58 at the time of the filing.

What KRRO share count was outstanding when the Form 144 was filed?

The Form 144 states that 14,725,646 shares of Korro Bio common stock were outstanding as of September 11, 2026. This figure is provided as context for the size of the proposed Rule 144 sale.

What prior KRRO share sales by James O. Dolan are disclosed?

The notice lists sales of 3,383 shares on June 16, 2026 for $36,638.23, 7,347 shares on September 8, 2026 for $99,285.52, and 6 shares on September 9, 2026 for $81.62, all of Korro Bio common stock.

On which market is KRRO common stock referenced in the filing?

The Rule 144 notice identifies the market for the common stock as NASDAQ, in connection with the planned sale of 5 shares of Korro Bio common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 04:26 PM Accepted by SEC EDGAR 09/11/2026 - 04:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002053835
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Korro Bio, Inc.
SEC File Number	001-39062
Address of Issuer	60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE MASSACHUSETTS 02141
Phone	617-468-1999
Name of Person for Whose Account the Securities are To Be Sold	Dolan Oliver
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5	68.58	14725646	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/15/2026	Restricted Stock Vesting	Issuer			5	06/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James O. Dolan 60 First Street 2nd Floor, Suite 250 Cambridge MA 02141	Common	06/16/2026	3383	36638.23
James O. Dolan 60 First Street 2nd Floor, Suite 250 Cambridge MA 02141	Common	09/08/2026	7347	99285.52
James O. Dolan 60 First Street 2nd Floor, Suite 250 Cambridge MA 02141	Common	09/09/2026	6	81.62

144: Remarks and Signature

Remarks
Date of Notice	09/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Emily Navaro, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for James O. Dolan.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)